Rainbow Connection - Articles

It's in Their DNA: Avera Health Uses Pharmacogenomics, MEDITECH EHR to Drive Precision

WESTWOOD, Mass., Feb. 7, 2017 /PRNewswire/ -- When a 2013 study suggested that pharmacogenomics, the study of how genes
affect an individual's response to medication, could be used to improve the quality and safety of patient care, MEDITECH customer Avera
Health (Sioux Falls, SD) made the commitment to transform paper-oriented workflows at their state-of-the-art human molecular genetics
laboratory, Avera Institute for Human Genetics (AIHG). Avera's IT Committee realized the importance of leveraging their MEDITECH
Electronic Health Record (EHR) for pharmacogenomics, and have used a three-phased approach for their improvement project—
documentation, ordering, and clinical decision support alerts.

Avera's clinical integration team implemented processes that incorporate pharmacogenomics into the clinical workflow, putting valuable
genetic information in front of providers at the point of medication ordering.

In addition, by automating pharmacogenomics into the clinicians' workflow, Avera has enabled providers to:

  • Order the patient's optimal pain medication at the outset
  • Reduce medication side effects
  • Improve treatment success
  • Contribute to shorter lengths of stay.

"Avera Health is proud of our efforts in leveraging the MEDITECH EHR to incorporate pharmacogenomics right at the provider's fingertips
for improved workflows and advanced patient care," Chief Medical Information Officer of Avera Health, Kim Jundt, MD said. "We value our
partnership with MEDITECH in providing the highest quality of care to our community."

For Avera, one of the most important aspects of preemptive testing was to have an alerting process in place for providers who will treat
the patient during future care episodes. Rules created in MEDITECH's CPOE solution flag the provider based on the results of the
patient's pain genotyping panel. In addition, a "duplicate order" alert informs the provider that the patient has already had pain
genotyping, and the once-in-a-lifetime lab test is not needed again.

"By leveraging the power and clinical sophistication of the MEDITECH EHR, Avera is transforming and improving the quality and safety of
patient care," MEDITECH Associate Vice President of Marketing, Christine Parent said. "We're proud to partner with this progressive
healthcare organization in providing the actionable data needed to impact clinical decision making."

For more information on how Avera converted pharmacogenomic results to actionable data for clinical decision making, download
MEDITECH's new case study, "It's in Their DNA: Avera Health Drives Precision Medicine at the Point of Care."
Hawaii Chapter Articles
President's Message

Hawaii Chapter Rainbow Connection Articles is now available online!  We are excited to feature articles from board
members and members like you!  If you have an article to share, please contact me at cassandra.stewart@meddata.com.

Below is an article from Meditech one of our Ali`i Sponsors who have supported your chapter throughout the past years